Biomarkers and clinical scoring systems in community-acquired pneumonia

Community-acquired pneumonia (CAP) is the third most common cause of death globally. Due to the complexity of CAP, it is widely accepted that, currently, clinical prognosis and diagnosis is inadequate for the assessment of the severity of the disease. With the aim to determining the initial treatmen...

Full description

Bibliographic Details
Main Authors: Meropi Karakioulaki, Daiana Stolz
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2019-01-01
Series:Annals of Thoracic Medicine
Subjects:
Online Access:http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=165;epage=172;aulast=Karakioulaki
id doaj-419eb2e10a714fbca89d71020023b96b
record_format Article
spelling doaj-419eb2e10a714fbca89d71020023b96b2020-11-24T21:26:39ZengWolters Kluwer Medknow PublicationsAnnals of Thoracic Medicine1817-17371998-35572019-01-0114316517210.4103/atm.ATM_305_18Biomarkers and clinical scoring systems in community-acquired pneumoniaMeropi KarakioulakiDaiana StolzCommunity-acquired pneumonia (CAP) is the third most common cause of death globally. Due to the complexity of CAP, it is widely accepted that, currently, clinical prognosis and diagnosis is inadequate for the assessment of the severity of the disease. With the aim to determining the initial treatment and the appropriate level of intervention, several clinical scores of severity and biomarkers have been developed. Both biomarkers and clinical scoring systems are expected to determine the different aspects of the host factor and the response to therapy, in order for physicians to be able to make an accurate benefit/risk assessment that will lead to proper diagnosis and correct prescription of antibiotics. This review aims to highlight the prognostic and diagnostic accuracy of various laboratory and clinical parameters in CAP and discuss the perspectives for the reduction of CAP mortality.http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=165;epage=172;aulast=KarakioulakiBiomarkerscommunity-acquired pneumoniaclinical scoring systems
collection DOAJ
language English
format Article
sources DOAJ
author Meropi Karakioulaki
Daiana Stolz
spellingShingle Meropi Karakioulaki
Daiana Stolz
Biomarkers and clinical scoring systems in community-acquired pneumonia
Annals of Thoracic Medicine
Biomarkers
community-acquired pneumonia
clinical scoring systems
author_facet Meropi Karakioulaki
Daiana Stolz
author_sort Meropi Karakioulaki
title Biomarkers and clinical scoring systems in community-acquired pneumonia
title_short Biomarkers and clinical scoring systems in community-acquired pneumonia
title_full Biomarkers and clinical scoring systems in community-acquired pneumonia
title_fullStr Biomarkers and clinical scoring systems in community-acquired pneumonia
title_full_unstemmed Biomarkers and clinical scoring systems in community-acquired pneumonia
title_sort biomarkers and clinical scoring systems in community-acquired pneumonia
publisher Wolters Kluwer Medknow Publications
series Annals of Thoracic Medicine
issn 1817-1737
1998-3557
publishDate 2019-01-01
description Community-acquired pneumonia (CAP) is the third most common cause of death globally. Due to the complexity of CAP, it is widely accepted that, currently, clinical prognosis and diagnosis is inadequate for the assessment of the severity of the disease. With the aim to determining the initial treatment and the appropriate level of intervention, several clinical scores of severity and biomarkers have been developed. Both biomarkers and clinical scoring systems are expected to determine the different aspects of the host factor and the response to therapy, in order for physicians to be able to make an accurate benefit/risk assessment that will lead to proper diagnosis and correct prescription of antibiotics. This review aims to highlight the prognostic and diagnostic accuracy of various laboratory and clinical parameters in CAP and discuss the perspectives for the reduction of CAP mortality.
topic Biomarkers
community-acquired pneumonia
clinical scoring systems
url http://www.thoracicmedicine.org/article.asp?issn=1817-1737;year=2019;volume=14;issue=3;spage=165;epage=172;aulast=Karakioulaki
work_keys_str_mv AT meropikarakioulaki biomarkersandclinicalscoringsystemsincommunityacquiredpneumonia
AT daianastolz biomarkersandclinicalscoringsystemsincommunityacquiredpneumonia
_version_ 1725978247225671680